pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group: Myeloma Canada
Name of drug and indication under review: Daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy

1. Conflict of Interest Declarations
To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency – it does not negate or preclude the use of the patient advocacy group input. Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
   □ No
   X Yes

   If no, please go to Section B

2. What form of payment did this patient advocacy group receive? (Check all that apply.)
   □ Operating
   □ Program Funding (e.g., Funds website)
   □ Royalties
   X Research/educational grants
   □ Gifts
   X Sponsorship of Events
   □ Honoraria
   □ Other, please specify: ____________________________

   Please provide the names of companies and organizations and the amounts of the payments in the box below.

   For the last fiscal year 2016 revenue source have come from the following companies: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Gleave, Janssen, Karyopharm, Lundbeck, Merck, Novartis, Otsuka, Sanofi, Takeda and The Binding Site.

   Some funding referred to below, as received by the corporation, is subject to confidentiality provisions in the agreements governing the funding.
### Source of funding

<table>
<thead>
<tr>
<th>Source</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Other pharma (including Janssen)</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Non related pharma</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

### Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

**NO**

### Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer’s parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

**NO**

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: **March 16, 2017**

Name: Martine Elias

Signature: [Signature]

Page 2 of 2